Not all neurosarcoidosis presentations carry the same severity. This protocol is specific to patients with mild to moderately disabling neurologic involvement — a distinct sub-group where treatment goals and regimen selection differ from severely disabling disease.
This protocol applies when neurologic impairment is present but not severely disabling, involving one or more of:
The recommended approach is an oral corticosteroid regimen, started at a therapeutic dose and tapered incrementally once clinical response is established, with a defined maintenance target. The complete regimen — including dose, taper schedule, and maintenance level — is set out in the full structured protocol.
The primary target is clinical neurologic improvement.
It is suggested that patients with mild to moderately disabling disease (cranial nerves II and VIII, meningeal mass lesions, hydrocephalus, CNS parenchymal disease, neuropathies and generalized myopathies) be treated with 20-30 mg prednisone daily for at least one month.
If the patient improves, the dose can be decreased by 5 mg every two weeks as the clinical course is monitored.
Patients may require a maintenance dose of 10 mg or lower daily even if they are treated with adjuvant drugs.
View source ↗